

Citations and Reference Literature: Vitamin K

Citations

1. Schurgers LJ, Teunissen KJ, Hamulyak K et al. Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. *Blood* 2006;109(8):3279-3283.
2. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 1997;21:357-365.
3. Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6 Suppl 1:S43-S45.
4. Shirakawa H, Komai M, Kimura S. Antibiotic-induced vitamin K deficiency and the role of the presence of intestinal flora. *Int J Vitam Nutr Res* 1990;60:245-251.
5. Stieger R, Baumgartner K, Neff U. [Dangerous hypoprothrombinemic hemorrhage in antibiotic therapy]. *Helv Chir Acta* 1992;58:775-778.
6. Kimura S, Satoh H, Komai M. The roles of intestinal flora and intestinal function on vitamin K metabolism. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:425-428.
7. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. *Clin Invest Med* 1994;17:531-539.
8. Clark J, Hochman R, Rolla AR et al. Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure. *Clin Exp Dial Apheresis* 1983;7:177-190.
9. Spurling NW, Harcourt RA, Hyde JJ. An evaluation of the safety of cefuroxime axetil during six months oral administration to beagle dogs. *J Toxicol Sci* 1986;11:237-277.
10. Schafer H, Naber K, Adam D. [Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain: a randomized pilot study]. *Arzneimittelforschung* 1989;39:1156-1162.
11. Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA. Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. *Arch Surg* 1991;126:524-525.
12. Peetermans W, Verbist L. [Coagulation disorders caused by cephalosporins containing methylthiotetrazole side chains]. *Acta Clin Belg* 1990;45:327-333.
13. Breen GA, St Peter WL. Hypoprothrombinemia associated with cefmetazole. *Ann Pharmacother* 1997;31:180-184.
14. Lipsky JJ. Nutritional sources of vitamin K. *Mayo Clin Proc* 1994;69:462-466.
15. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. *Curr Opin Infect Dis* 2002;15:501-506.
16. Montalto M, Arancio F, Izzi D et al. [Probiotics: history, definition, requirements and possible therapeutic applications]. *Ann Ital Med Int* 2002;17:157-165.
17. Morelli L. Probiotics: clinics and/or nutrition. *Dig Liver Dis* 2002;34 Suppl 2:S8-S11.
18. Ouwehand A, Vesterlund S. Health aspects of probiotics. *IDrugs* 2003;6:573-580.
19. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. *Clin Microbiol Rev* 2003;16:658-672.
20. Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria? *Curr Issues Intest Microbiol* 2003;4:53-60.
21. Olson RE. Vitamin K. In: Shils ME, Olson JA, Shike M, eds. *Modern Nutrition in Health and Disease*. 9th ed. Media, Pa: Williams & Wilkins; 1999:363-380.
22. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. *Hematol Oncol Clin North Am* 2000;14:339-353.
23. Verho M, Malerczyk V, Rosenkranz B, Grottsch H. Absence of interaction between ofloxacin and phenprocoumon. *Curr Med Res Opin* 1987;10:474-479.
24. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. *Am J Gastroenterol* 1994;89:915-923.
25. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996;82:610-612.
26. Huilgol VR, Markus SL, Vakil NB. Antibiotic-induced iatrogenic hemobilia. *Am J Gastroenterol* 1997;92:706-707.
27. Suzuki K, Fukushima T, Meguro K et al. Intracranial hemorrhage in an infant owing to vitamin K deficiency despite prophylaxis. *Childs Nerv Syst* 1999;15:292-294.
28. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. *Ann Pharmacother* 2002;36:1554-1557.
29. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. *Ann Pharmacother* 2003;37:367-370.
30. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. *Gut* 1975;16:93-98.
31. Hathcock JN. Metabolic mechanisms of drug-nutrient interactions. *Fed Proc* 1985;44:124-129.

Citations and Reference Literature: Vitamin K

32. Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. *Dig Dis Sci* 1985;30:477-482.
33. Roe DA. *Drug-Induced Nutritional Deficiencies*. 2nd ed. Westport, Conn: Avi Publishing; 1985.
34. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. *Med Toxicol* 1987;2:10-32.
35. Roe DA. Drug and nutrient interactions in the elderly diabetic. *Drug Nutr Interact* 1988;5:195-203.
36. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. *Arch Dis Child* 1996;74:157-160.
37. Booth SL, Broe KE, Gagnon DR et al. Vitamin K intake and bone mineral density in women and men. *Am J Clin Nutr* 2003;77:512-516.
38. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. *Calcif Tissue Int* 2000;66:123-128.
39. Inoue T, Sugiyama T, Matsubara T et al. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. *Endocr J* 2001;48:11-18.
40. Elmstahl S, Ekstrom H, Galvard H et al. Is there an association between inhaled corticosteroids and bone density in postmenopausal women? *J Allergy Clin Immunol* 2003;111:91-96.
41. Leone FT, Fish JE, Szeffler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. *Chest* 2003;124:2329-2340.
42. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. *Am J Respir Crit Care Med* 2004;169:83-88.
43. Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. *Am J Dis Child* 1987;141:1210-1212.
44. Diarrhea and constipation. In: Berkow R, Fletcher AJ, Beers MH et al, eds. *The Merck Manual of Diagnosis and Therapy*. 16th ed. Rahway, NJ: Merck Research Laboratories; 1992:810.
45. Keith DA, Gallop PM. Phenytoin, hemorrhage, skeletal defects and vitamin K in the newborn. *Med Hypotheses* 1979;5:1347-1351.
46. Howe AM, Lipson AH, Sheffield LJ et al. Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. *Am J Med Genet* 1995;58:238-244.
47. Keith DA, Gundberg CM, Japour A et al. Vitamin K-dependent proteins and anticonvulsant medication. *Clin Pharmacol Ther* 1983;34:529-532.
48. Cornelissen M, Steegers-Theunissen R, Kollee L et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. *Am J Obstet Gynecol* 1993;168:923-928.
49. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. *Neurology* 2002;58:549-553.
50. Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. *Arch Dis Child Fetal Neonatal Ed* 1999;81:F208-F210.
51. Gage BF, Birman-Deych E, Radford MJ et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. *Arch Intern Med* 2006;166:241-246.
52. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *J Am Coll Cardiol* 2003;41:1633-1652.
53. Crowther MA, Julian J, McCarty D et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. *Lancet* 2000;356:1551-1553.
54. Crowther MA, Douketis JD, Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. *Ann Intern Med* 2002;137:251-254.
55. Lubetsky A, Yonath H, Olchovsky D et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. *Arch Intern Med* 2003;163:2469-2473.
56. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. *Arch Intern Med* 2002;162:1893-1896.
57. Lubetsky A, Dekel-Stern E, Chetrit A et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. *Thromb Haemost* 1999;81:396-399.
58. Cushman M, Booth SL, Possidente CJ et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. *Br J Haematol* 2001;112:572-577.
59. Lappegard KT. [Hereditary warfarin resistance]. *Tidsskr Nor Laegeforen* 2000;120:3257-3258.

Citations and Reference Literature: Vitamin K

60. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. *Clin Chim Acta* 2001;308:9-15.
61. Linder MW, Valdes R Jr. Genetic mechanisms for variability in drug response and toxicity. *J Anal Toxicol* 2001;25:405-413.
62. Iqbal O. Pharmacogenomics in anticoagulant drug development. *Pharmacogenomics* 2002;3:823-828.
63. O'Reilly RA, Aggeler PM, Hoag MS et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs: the first reported kindred. *N Engl J Med* 1964;271:809-815.
64. O'Reilly RA, Aggeler PM. Coumarin anticoagulant drugs: hereditary resistance in man. *Fed Proc* 1965;24:1266-1273.
65. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. *Ann NY Acad Sci* 1968;151:913-931.
66. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. *N Engl J Med* 1970;282:1448-1451.
67. Alving BM, Strickler MP, Knight RD et al. Hereditary warfarin resistance: investigation of a rare phenomenon. *Arch Intern Med* 1985;145:499-501.
68. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002;72:702-710.
69. Cohen H, Scott SD, Mackie IJ et al. The development of hypoprothrombinaemia following antibiotic therapy in malnourished patients with low serum vitamin K1 levels. *Br J Haematol* 1988;68:63-66.
70. Feldstein AC, Smith DH, Perrin N et al. Reducing warfarin medication interactions: an interrupted time series evaluation. *Arch Intern Med* 2006;166:1009-1015.
71. Sconce EA, Daly AK, Khan TI et al. APOE genotype makes a small contribution to warfarin dose requirements. *Pharmacogenet Genomics* 2006;16:609-611.
72. Sconce EA, Kamali F. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. *Eur J Haematol* 2006;77:457-462.
73. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. *Blood* 2006.
74. Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. *Cleve Clin J Med* 2003;70:361-371.
75. Sadowski JA, Booth SL, Mann KG et al. Structure and mechanism of activation of vitamin K antagonists. In: Poller L et al, eds. *Oral anticoagulants*. London: Arnold; 1996:439-442.
76. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. *Am J Med* 2004;116:651-656.
77. Harrell CC, Kline SS. Vitamin K-supplemented snacks containing olestra: implication for patients taking warfarin. *JAMA* 1999;282:1133-1134.
78. McDuffie JR, Calis KA, Booth SL et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. *Pharmacotherapy* 2002;22:814-822.
79. Merkel RL. The use of menadione bisulfite and ascorbic acid in the treatment of nausea and vomiting of pregnancy: a preliminary report. *Am J Obstet Gynecol* 1952;64:416-418.
80. Venugopal M, Jamison JM, Gilloteaux J et al. Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell lines. *Cell Biol Int* 1996;20:787-797.
81. Gilloteaux J, Jamison JM, Arnold D et al. Cancer cell necrosis by autschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. *Scanning* 1998;20:564-575.
82. Zhang W, Negoro T, Satoh K et al. Synergistic cytotoxic action of vitamin C and vitamin K3. *Anticancer Res* 2001;21:3439-3444.
83. Gilloteaux J, Jamison JM, Arnold D et al. Ultrastructural aspects of autschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. *Ultrastruct Pathol* 2001;25:183-192.
84. Gilloteaux J, Jamison JM, Arnold D, Summers JL. Autschizis: another cell death for cancer cells induced by oxidative stress. *Ital J Anat Embryol* 2001;106:79-92.
85. Booth SL, Golly I, Sackeck JM et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. *Am J Clin Nutr* 2004;80:143-148.

Reference Literature

- [No authors listed.] ACCP-NHLBI National Conference on Antithrombotic Therapy: American College of Chest Physicians and the National Heart, Lung and Blood Institute. *Chest* 1986;89(2 Suppl):1S-106S.
- [No author listed.] Aquamephyton (phytonadione), product prescribing information. Whitehouse Station, NJ: Merck and Co, Inc; 2001.
- [No author listed.] Coumadin (warfarin), product prescribing information. Wilmington, DE: DuPont Pharma; 2001.

Citations and Reference Literature: Vitamin K

- Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. *Thromb Haemost* 2002;88(1):48-51.
- Aisaka K, Uesato T, Miwa, et al. Evaluation of vitamin K2 (menatetrenone) administration with hormone replacement therapy on prevention of osteoporosis in climacteric women. Ninth International Menopause Society World Congress on the Menopause: Yokohama, Japan, Oct 1999:79-83.
- Alberts MJ, Massey EW, Dawson D. A multicenter study of anticoagulation parameters when using heparin and warfarin. *Arch Neurol* 1987;44(12):1229-1231.
- Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA* 2005;294:3108-3116.
- Allison AC. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. *Med Hypotheses* 2001;57(2):151-155.
- Allison PM, Mummah-Schendel LL, Kindberg CG, et al. Effects of a vitamin K-deficient diet and antibiotics in normal human volunteers. *J Lab Clin Med* 1987;110(2):180-188.
- Alperin JB. Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. *JAMA* 1987;258(14):1916-1919.
- Andersen P, Godal HC. Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K. *Acta Med Scand* 1975;198:269-270.
- Ansell JE. The perioperative management of warfarin therapy. *Arch Intern Med* 2003;163:881-883.
- Anonymous. New examples of vitamin K-drug interaction. *Nutr Rev* 1984;42(4):161-163. (Review)
- Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019). *Eur J Clin Nutr* 2000;54:263-267.
- Avery RA, Duncan WE, Alving BM. Severe vitamin K deficiency induced by occult celiac disease BR96-026. *Am J Hematol* 1996;53(1):55.
- Barash P, Kitahata LM, Mandel S. Acute cardiovascular collapse after intravenous phytonadione. *Anesth Analg* 1976;55(2):304-306.
- Bell RG. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. *Fed Proc* 1978;37(12):2599-2604. (Review)
- Bell RG, Caldwell PT, Holm EE. Coumarins and the vitamin K-K epoxide cycle: lack of resistance to coumatetralyl in warfarin-resistant rats. *Biochem Pharmacol* 1976;25(9):1067-1070.
- Bell RG, Ren P. Inhibition by warfarin enantiomers of prothrombin synthesis, protein carboxylation, and the regeneration of vitamin K from vitamin K epoxide. *Biochem Pharmacol* 1981;30(14):1953-1958.
- Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. *Gut* 1998;42(1):2-7. (Review)
- Binkley N, Suttie J. Vitamin K nutrition and osteoporosis. *J Nutr* 1995;125:1812-1821.
- Blum S, Haller D, Pfeifer A, et al. Probiotics and immune response. *Clin Rev Allergy Immunol* 2002;22(3):287-309.
- Bodin L, Verstuyft C, Tregouet D-A, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood* 2005;106:135-140.
- Booth SL, Broe KE, Gagnon DR, et al. Vitamin K intake and bone mineral density in women and men. *Am J Clin Nutr* 2003;77(2):512-516.
- Booth SL, Broe KE, Peterson JW, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. *J Clin Endocrinol Metab* 2004;89(10):4904-4909.
- Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 content. *Thromb Haemost* 1997;77:504-509.
- Booth SL, Lichtenstein AH, O'Brien-Morse M, et al. Effects of a hydrogenated form of vitamin K on bone formation and resorption. *Am J Clin Nutr* 2001;74(6):783-790.
- Booth SL, Martini L, Peterson JW, et al. Dietary phylloquinone depletion and repletion in older women. *J Nutr* 2003;133(8):2565-2569.
- Booth SL, Broe KE, McLean RR, et al. Low vitamin K status is associated with low bone mineral density and quantitative ultrasound in men. Presentation at 24th Annual Meeting of the American Society for Bone and Mineral Research. San Antonio, Sep 23, 2002.
- Bovill EG, Lawson J, Sadowski J, et al. Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: implications for warfarin therapy. In: Ezekowitz, MD, ed. *The heart as a source of systemic embolisation*. New York: Martin Dekker; 1992.
- Braam LA, Knapen MH, Geusens P, et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. *Calcif Tissue Int* 2003;73(1):21-26.
- Brown CH, Natelson EA, Bradshaw MW, et al. The hemostatic defect produced by carbenicillin. *N Engl J Med* 1974;291:265-270.
- Burnier JP, Borowski M, Furie BC, et al. Gamma-carboxyglutamic acid. *Mol Cell Biochem* 1981;39:191-207.

Citations and Reference Literature: Vitamin K

- Byrd DC, Stephens MA, Hamann GL, et al. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio. *Am J Health Syst Pharm* 1999;56(22):2312-2315.
- Canfield AE, Farrington C, Dziobon MD, et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. *J Pathol* 2002;196(2):228-234.
- Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. *J Clin Invest* 1996;98:1619-1625.
- Clarke P, Mitchell SJ, Wynn R, et al. Vitamin K prophylaxis for preterm infants: a randomized, controlled trial of 3 regimens. *Pediatrics* 2006;118:1657-1666.
- Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166:1256-1261. (Meta-analysis)
- Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. *Res Commun Chem Pathol Pharmacol* 1976;13(1):109-114.
- Conly JM, Stein K, Worobetz L, et al. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. *Am J Gastroenterol* 1994;89(6):915-923.
- Corallo CE, Gillett M. Anaphylactic shock following intravenous vitamin K1. *Aust J Hosp Pharm* 1997;27:146-147.
- Corrigan JJ Jr. The effect of vitamin E on warfarin-induced vitamin K deficiency. *Ann N Y Acad Sci* 1982;393:361-368.
- Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. *Am J Obstet Gynecol* 1993;168(3 Pt 1):884-888.
- Covington T, ed. Nonprescription drug therapy guiding patient self-care. St Louis: Facts and Comparisons; 1999:467-545.
- Craciun AM, Wolf J, Knapen MH, et al. Improved bone metabolism in female elite athletes after vitamin K supplementation. *Int J Sports Med* 1998;19(7):479-484.
- Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 1997;21(6):357-365. (Review)
- De Simone C, Vesely R, Bianchi SB, et al. The role of probiotics in modulation of the immune system in man and in animals. *Int J Immunother* 1993;9:23-28.
- DeZee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. *Arch Intern Med* 2006;166:391-397.
- Diab F, Feffer S. Hereditary warfarin resistance. *South Med J* 1994;87(3):407-409. (Review)
- Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants: a systematic review. *Arch Intern Med* 2003;163:901-908. (Review)
- Engelse MA, Neele JM, Bronckers AL, et al. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis. *Cardiovasc Res* 2001;52(2):281-289.
- Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. *J Nutr* 2000;130(2S Suppl):403S-409S. (Review)
- Feldstein AC, Smith DH, Perrin N, et al. Reducing warfarin medication interactions: an interrupted time series evaluation. *Arch Intern Med* 2006;166:1009-1015.
- Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. *Am J Clin Nutr* 1999;69(1):74-79.
- Franco V, Polanczyk CA, Clausell N, et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. *Am J Med* 2004;116(10):651-656.
- Frey UH, Aral N, Muller N, et al. Cooperative effect of GNB3 825C>T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation. *Thromb Res* 2003;109(5-6):279-286.
- Fuller R, Gibson GR. Modification of the intestinal microflora using probiotics and prebiotics. *Scand J Gastroenterol Suppl* 1997;222:28-31.
- Fuller R. Probiotics in human medicine. *Gut* 1991;32(4):439-442. (Review)
- Gage BF, Birman-Deych E, Radford MJ, et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation. *Arch Intern Med* 2006;166:241-246.
- Garcia D, Libby E. A survey examining oral vitamin K use among anticoagulation clinics in the southwestern United States. Presented at the Eighteenth Congress of the International Society on Thrombosis and Haemostasis (ISTH). Paris, Jul 8, 2001.
- Gibson GR. Dietary modulation of the human gut microflora using probiotics. *Br J Nutr* 1998;80(Suppl 2):S209-S212.
- Gilloteaux J, Jamison JM, Arnold D, et al. Autoschizis: another cell death for cancer cells induced by oxidative stress. *Ital J Anat Embryol* 2001;106(2 Suppl 1):79-92.

Citations and Reference Literature: Vitamin K

- Gilloteaux J, Jamison JM, Arnold D, et al. Cancer cell necrosis by autophagocytosis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. *Scanning* 1998;20(8):564-575.
- Gilloteaux J, Jamison JM, Arnold D, et al. Ultrastructural aspects of autophagocytosis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. *Ultrastruct Pathol* 2001;25(3):183-192.
- Glasheen JJ, Fugit RV, Prochazka AV. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy: a comment. *Pharmacotherapy* 2003;23(8):1079-1080. (Letter)
- Goss TF, Walawander CA, Grasela TH Jr, et al. Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patients. *Pharmacotherapy* 1992;12(4):283-291.
- Harrell CC, Kline SS. Oral vitamin K1: an option to reduce warfarin's activity. *Ann Pharmacother* 1995;29(12):1228-1232.
- Harris JE. Interaction of dietary factors with oral anticoagulants: review and application. *J Am Diet Assoc* 1995;95(5):580-584. (Review)
- Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. *Arch Pathol Lab Med* 1987;111(8):719-722.
- Hart JP, Shearer MJ, Klenerman L, et al. Electrochemical detection of depressed circulating levels of vitamin K in osteoporosis. *J Clin Endocrinol Metab* 1985;60(6):1268-1269.
- Hart RG. Atrial fibrillation and stroke prevention [perspective]. *N Engl J Med* 2003;349:1015-1016. (Editorial)
- Hathcock JN. Metabolic mechanisms of drug-nutrient interactions. *Fed Proc* 1985;44(1 Pt 1):124-129. (Review)
- Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm* 2000;57:1221-1230.
- Hey E. Vitamin K: what, why, and when. *Arch Dis Child Fetal Neonatal Ed* 2003;88(2):F80-83.
- Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6(Suppl 1):S43-45. (Review)
- Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. *Pharmacogenetics* 2004;14(8):539-547.
- Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. *Clin Med Res* 2005;3(3):137-145.
- Hirsh J, Dalen J, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis: American College of Chest Physicians. *Chest* 2001;119(1 Suppl):1S-370S.
- Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest* 2001;119(1 Suppl):8S-21S. (Review)
- Hirsh J, Fuster V, Ansell J, et al; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *Circulation* 2003;107(12):1692-711. (Review)
- Hodges SJ, Pilkington MJ, Shearer MJ, et al. Age-related changes in the circulating levels of congeners of vitamin K2, menaquinone-7 and menaquinone-8. *Clin Sci (Colch)* 1990;78(1):63-66.
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med* 2005;165:1095-1106.
- Holt RJ, Freytes CO. Familial warfarin resistance. *Drug Intell Clin Pharm* 1983;17(4):281-283.
- Holzappel WH, Haberer P, Snel J, et al. Overview of gut flora and probiotics. *Int J Food Microbiol* 1998;41(2):85-101. (Review)
- Howe AM, Webster WS, Lipson AH, et al. Binder's syndrome due to prenatal vitamin K deficiency: a theory of pathogenesis. *Aust Dent J* 1992;37(6):453-460.
- Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. *Pharmacotherapy* 1996;16(6):1009-1017. (Review)
- Humpl T, Bruhl K, Brzezinska R, et al. Fatal late vitamin K-deficiency bleeding after oral vitamin K prophylaxis secondary to unrecognized bile duct paucity. *J Pediatr Gastroenterol Nutr* 1999;29(5):594-597.
- Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003;349:1019-1026.
- Igarashi O. Vitamin K. *Nippon Rinsho* Apr 1993;51(4):910-918.
- Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women: a comparative study with vitamin D3 and estrogen-progestin therapy. *Maturitas* 1999;31(2):161-164.
- Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. *Cleve Clin J Med* 2003;70(4):361-371.
- Jie KS, Bots ML, Vermeer C, et al. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. *Atherosclerosis* 1995;116(1):117-123.
- Jie KS, Gijsbers BL, Knäpen MH, et al. Effects of vitamin K and oral anticoagulants on urinary calcium excretion. *Br J Haematol* 1993;83(1):100-104.

Citations and Reference Literature: Vitamin K

- Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent-carboxylation resides on the propeptide of factor IX. *Cell* 1987;48:185-191.
- Kanai T, Takagi T, Masuhiro K, et al. Serum vitamin K level and bone mineral density in post-menopausal women. *Int J Gynaecol Obstet* 1997;56(1):25-30.
- Kasper H. Protection against gastrointestinal diseases: present facts and future developments. *Int J Food Microbiol* 1998;41(2):127-131.
- Kempin SJ. Warfarin resistance caused by broccoli. *N Engl J Med* 1983;308(20):1229-1230. (Letter)
- Kendall MJ, Chan K. Drug-induced malabsorption. *Xenobiotica* 1973;3(11):727-744. (Review)
- Keough GC, English JC, Meffert JJ. Eczematous hypersensitivity from aqueous vitamin K injection. *Cutis* 1998;61:81-83.
- Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. *Blood Purif* 2002;20(5):473-476.
- Kikuchi S, Ando A, Minato K. [Acquired coagulopathy caused by administration of parenteral broad-spectrum antibiotics.] *Rinsho Byori* 1991;39(1):83-90. [Japanese]
- Kimura S, Satoh H, Komai M. The roles of intestinal flora and intestinal function on vitamin K metabolism. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:425-428.
- Knapen MH, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. *Ann Intern Med* 1989 D15;111(12):1001-1005.
- Kohlmeier M, Saupe J, Shearer MJ, et al. Bone health of adult hemodialysis patients is related to vitamin K status. *Kidney Int* 1997;51:1218-1221.
- Lackey L, Ozawa T. Cephalosporins and coagulopathy. *J Tenn Med Assoc* 1986;79(10):613-615. (Review)
- Laupacis A. Oral vitamin K reversed warfarin-associated coagulopathy faster than subcutaneous vitamin K. *ACP J Club* 2003;138(1):10.
- Lee AW, Proudfoot WH, Griffen WO Jr. Coagulopathy associated with broad spectrum antibiotic therapy. *J Ky Med Assoc* 1984;82(3):125-126.
- Lee CR. Warfarin initiation and the potential role of genomic-guided dosing. *Clin Med Res* 2005;3(4):205-206. (Editorial)
- Lefrere JJ, Guyon F, Horellou MH, et al. [Resistance to vitamin K antagonists: 6 cases.] *Ann Med Interne (Paris)* 1986;137(5):384-390. [French]
- Linzenmeier G, Haralambie E, Dermoumi H. [Short-term oral chemoprophylaxis before intestine surgery: quantitative determination of bacteria and fungi in stool specimens.] *Zentralbl Bakteriol [Orig A]* 1979;243(2-3):326-335. [German]
- Lipkin EW, Kowdley KV. Vitamin K replacement in osteoporosis associated with cirrhosis: another reason to "eat your vegetables?" *Am J Gastroenterol* 2002;97(4):786-788. (Editorial)
- Lipsky JJ. Nutritional sources of vitamin K. *Mayo Clin Proc* 1994;69(5):462-466. (Review)
- Lubetsky A, Shasha Y, Olchovsky D, et al. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. *Thromb Haemost* 2003;90(1):71-76.
- Matteuzzi D, Crociani F, Brigidi P. Antimicrobial susceptibility of bifidobacterium. *Ann Microbiol (Paris)* 1983;134A(3):339-349.
- McKeown NM, Jacques PF, Gundberg CM, et al. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. *J Nutr* 2002;132(6):1329-1334.
- McLean RR, Booth SL, Kiel DP, et al. Association of dietary and biochemical measures of vitamin K with quantitative ultrasound of the heel in men and women. *Osteoporos Int* 2006;17(4):600-607.
- Merkel R. The use of menadione bisulfite and ascorbate in the treatment of nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 1952;416-418.
- Miki T, Nakatsuka K, Naka H, et al. Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. *J Bone Miner Metab* 2003;21(3):161-165.
- Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. *Chest* 2001;119(1 Suppl):344S-370S.
- Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. *Clin Pharmacol Ther* 1969;10(1):22-35.
- Nakamura K, Toyohira H, Kariyazono H, et al. Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces. *Artery* 1994;21(3):148-160.
- Nieuwenhuys CM, Feijge MA, Vermeer C, et al. Vitamin K-dependent and vitamin K-independent hypocoagulant effects of dietary fish oil in rats. *Thromb Res* 2001;104(2):137-147.
- Noto V, Taper HS, Jiang YH, et al. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro: I: synergism of combined vitamin C and K3 action. *Cancer* 1989;63(5):901-906.
- Oldenburg J, Quenzel E-M, Harbrecht V, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. *Br J Haematol* 1997;98:240-244.

Citations and Reference Literature: Vitamin K

- Olson JA. Recommended dietary intakes (RDI) of vitamin K in humans. *Am J Clin Nutr* 1987;45(4):687-692.
- Olson RE. Vitamin K. In: Shils ME, Olson JA, Shike M, eds. *Modern nutrition in health and disease*. 9th ed. Media, PA: Williams & Wilkins; 1999:363-380.
- O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs: the first reported kindred. *N Engl J Med* 1964;271:809-815.
- O'Reilly R, Rytand D. Resistance to warfarin due to unrecognized vitamin K supplementation. *N Engl J Med* 1980;303:160-161.
- Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. *Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc*. Washington, DC: National Academy Press; 2001:144.
- Panneerselvam S, Baglin C, Lefort W, et al. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. *Br J Haematol* 1998;103(2):422-424.
- Patel RJ, Witt DM, Saseen JJ, et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. *Pharmacotherapy* 2000;20(10):1159-1166.
- Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. *Arterioscler Thromb Vasc Biol* 1998;18(9):1400-1407.
- Ramsey PS, Rouse DJ. Therapies administered to mothers at risk for preterm birth and neurodevelopmental outcome in their infants. *Clin Perinatol* 2002;29(4):725-743. (Review)
- Ravnan SL, Locke C. Levofloxacin and warfarin interaction. *Pharmacotherapy* 2001;21(7):884-885.
- Richards, RK. Influence of fever upon the action of 3,3-methylene bis-(4-hydroxycoumarin). *Science* 1943;97:313-316.
- Riebert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. *Ann Allergy Asthma Immunol* 2002;89(4):400-406. (Review)
- Ringstrom E, Long H. Oral vitamin K for warfarin-associated coagulopathy. *Ann Intern Med* 2003;138(7):610-611. (Letter)
- Robinson JN, Banerjee R, Thiet MP. Coagulopathy secondary to vitamin K deficiency in hyperemesis gravidarum. *Obstet Gynecol* 1998;92(4 Pt 2):673-675.
- Roe DA. *Drug-induced nutritional deficiencies*. 2nd ed. Westport, CT: Avi Publishing; 1985:158-159.
- Roe DA. Drug and nutrient interactions in the elderly diabetic. *Drug Nutr Interact* 1988;5(4):195-203. (Review)
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Dekker; 1984:505-523.
- Sachdev GP, Ohlrogge KD, Johnson CL. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. *Am J Health Syst Pharm* 1999;56(15):1505-1514. (Review)
- Sadowski JA, Booth SL, Mann KG, et al. Structure and mechanism of activation of vitamin K antagonists. In: Poller L, Hirsh J, eds. *Oral anticoagulants*. London: Arnold; 1996:9-29.
- Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. *Eur J Clin Nutr* 2002;56(Suppl 3):S60-64. (Review)
- Schulman S. Care of patients receiving long-term anticoagulant therapy. *N Engl J Med* 2003;349(7):675-683. (Review, Tutorial)
- Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? *Blood* 2004;104:3231-3232.
- Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. *Z Kardiol* 2001;90(Suppl 3):57-63.
- Schurgers LJ, Shearer MJ, Hamulyák K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. *Blood* 2004;104:2682-2689.
- Schurgers LJ, Spronk HMH, Soute BAM, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. *Blood* 2006;doi:10.1182/blood-2006-07-035345.
- Schurgers LJ, Teunissen KJF, Hamulyák K, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. *Blood* 2006;doi:10.1182/blood-2006-08-040709.
- Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. *Biochim Biophys Acta* 2002;1570(1):27-32.
- Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. *Blood* 2006. Epub ahead of print.
- Sconce EA, Daly AK, Khan TI, et al. APOE genotype makes a small contribution to warfarin dose requirements. *Pharmacogenet Genomics* 2006;16(8):609-611.

Citations and Reference Literature: Vitamin K

- Sconce EA, Kamali F. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. *Eur J Haematol* 2006;77(6):457-462.
- Sconce EA, Khan TI, Daly AK, et al. The impact of simvastatin on warfarin disposition and dose requirements. *J Thromb Haemost* 2006;4(6):1422-1424.
- Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002;72(6):702-710.
- Shanahan CM, Proudfoot D, Farzaneh-Far A, et al. The role of Gla proteins in vascular calcification. *Crit Rev Eukaryot Gene Expr* 1998;8(3-4):357-375. (Review)
- Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. *Curr Opin Clin Nutr Metab Care* 2000;3(6):433-438. (Review)
- Shearer MJ. The roles of vitamins D and K in bone health and osteoporosis prevention. *Proc Nutr Soc* 1997;56(3):915-937. (Review)
- Shearer MJ. Vitamin K. *Lancet* 1995;345(8944):229-234.
- Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. *J Nutr* 1996;126(4 Suppl):1181S-1186S. (Review)
- Shearer MJ, Bechtold H, Andrassy K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. *J Clin Pharmacol* 1988;28(1):88-95.
- Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res* 2000;15(3):515-521.
- Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. *Lancet Oncol* 2003;4(4):224-233.
- Spronk HM, Soute BA, Schurgers LJ, et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. *Biochem Biophys Res Commun* 2001;289(2):485-490.
- Streif W, Andrew M, Marizinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. *Blood* 1999;94(9):3007-3014.
- Suttie JW, Muhah-Schendel LL, Shah DV, et al. Vitamin K deficiency from dietary vitamin K restriction in humans. *Am J Clin Nutr* 1988;47:475-480.
- Tam DA Jr, Myer EC. Vitamin K-dependent coagulopathy in a child receiving anticonvulsant therapy. *J Child Neurol* 1996;11(3):244-246.
- Taper HS, de Gerlache J, Lans M, et al. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. *Int J Cancer* 1987;40(4):575-579.
- Taper HS, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. *Anticancer Res* 1996;16(1):499-503.
- Tapson VF. The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy. *Clin Chest Med* 2003;24(1):139-151.vii.
- Thorp JA, O'Connor M, Belden B, et al. Effects of phenobarbital and multiple-dose corticosteroids on developmental outcome at age 7 years. *Obstet Gynecol* 2003;101(2):363-373.
- Tsugawa N, Shiraki M, Suhara Y, et al. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. *Am J Clin Nutr* 2006;83:380-386.
- van Dongen CJJ, Vink R, Hutten BA, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. *Arch Intern Med* 2003;163:1285-1293.
- van Haarlem LJ, Knapen MH, Hamulyak K, et al. Circulating osteocalcin during oral anticoagulant therapy. *Thromb Haemost* 1988;60(1):79-82.
- Vanscoy GJ, McAuley JW. Exaggerated warfarin sensitivity: a case report. *Vet Hum Toxicol* 1991;33(3):270-271.
- Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic antitumor activity of vitamins C and K3 on human urologic tumor cell lines. *Life Sci* 1996;59(17):1389-1400.
- Vermeer C, Braam L. Role of K vitamins in the regulation of tissue calcification. *J Bone Miner Metab* 2001;19(4):201-206. (Review)
- Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. *Hematol Oncol Clin North Am* 2000;14(2):339-353.
- Visser LE, Penning-van Bees FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. *Thromb Haemost* 2002;88(5):705-710.
- Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. *Thromb Haemost* 2005;93(4):700-705.

Citations and Reference Literature: Vitamin K

- Voora D, McLeod HL, Eby C, et al. The pharmacogenetics of coumarin therapy. *Pharmacogenomics* 2005;6(5):503-513.
- Voora D, McLeod HL, Eby C, et al. Use of pharmacogenetics to guide warfarin therapy. *Drugs Today (Barc)* 2004;40(3):247-257.
- Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells: a cell system which resembles the system in bone cells. *Thromb Haemost* 1999;82(6):1764-1767.
- Weber P. Vitamin K and bone health. *Nutrition* 2001;17(10):880-887.
- Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. *Ann Intern Med* 1997;126(12):959-962.
- Weideman R, Patel AP. Oral vitamin K for warfarin-associated coagulopathy. *Ann Intern Med* 2003;138(7):610. (Letter)
- Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994;121(9):676-683. (Review)
- Wilke RA, Berg RL, Vidaillet HJ, et al. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. *Clin Med Res* 2005;3(4):207-213.
- Wong DA, Freeman S. Cutaneous allergic reaction to intramuscular vitamin K1. *Australas J Dermatol* 1999;40:147-152.
- Yamreudeewong W, Lower DL, Kilpatrick DM, et al. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. *Pharmacotherapy* 2003;23(3):333-338.
- Yerby MS. Problems and management of the pregnant woman with epilepsy. *Epilepsia* 1987;28(Suppl 3):S29-36. (Review)
- Zhang W, Negoro T, Satoh K, et al. Synergistic cytotoxic action of vitamin C and vitamin K3. *Anticancer Res* 2001;21(5):3439-3444.